Caleco Pharma Corp.
OTC Bulletin Board : CAEH
FRANKFURT : T3R

Caleco Pharma Corp.

March 30, 2010 09:15 ET

Caleco Pharma Corp. Receives Delivery of Formulations by Cosmetic Project Management

BELLINGHAM, WASHINGTON--(Marketwire - March 30, 2010) - (OTCBB:CAEH)(FRANKFURT:T3R)(WKN:A0N9Y0) (www.calecopharmacorp.com) Caleco Pharma Corp. ("Caleco") is pleased to announce that Cosmetic Project Management, a Spanish corporation that provides product and market development support to cosmetic product manufacturers, has delivered to Caleco the commercial formulations of its Natural Hair Care Products (LamiriShampoo, LamiriHair Conditioner, LamiriHair Tonic) and Natural Skin Care Products (LamiriGel and LamiriCreme).

"We plan to initiate safety testing using these commercial grade formulations immediately. Our goal is to enter the European market by the second quarter of 2010 if we are successful in completing all of the safety testing. We also plan to commence clinical trials of these commercial grade formulations within 100 days, which is consistent with our dual-pathway commercialization model," said John Boschert, the Chief Executive Officer of Caleco.

Caleco's dermatologic products are of particular interest due to their "natural" sourcing and potential for efficacy. The natural cosmetic category continues to show a remarkable openness to new products, especially those that are based on natural resources and can show a benefit to health. In addition, Caleco's management and consulting team have considerable experience in successfully bringing new products to market in this area.

About Caleco Pharma Corp.

Caleco Pharma is focused on the ongoing research and development of its pipeline of over-the-counter and prescription medications including its proprietary antiviral and "Liver Health" OTC formulations. In addition Caleco Pharma is developing over-the-counter food supplements and dermatological products based on the active ingredients found in its proprietary formulation. To date, Caleco Pharma's intellectual property covering the Liver Health formulations and derivatives consists of patent applications in the United States, Europe and Canada and four European Drug Master File applications.

Caleco Pharma's shares are traded in the United States on the OTC Bulletin Board (OTCBB:CAEH) and in Germany on the Frankfurt Stock Exchange (WKN:A0N9Y0/ Symbol: T3R.FSE).

This press release may contain, in addition to historic information, forward-looking statements. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. In particular, there are no assurances that: (i) Caleco will be granted a patent in connection with its current patent applications in the United States, Europe and Canada; (ii) Caleco will be able to manufacture and produce its products or that its products will be effective; (iii) Caleco will be able to obtain any sales of the Natural Hair Care Products (LamiriShampoo, LamiriHair Conditioner, LamiriHair Tonic) and Natural Skin Care Products (LamiriGel and LamiriCreme); (iv) it will be able to carry out any pre-clinical or clinical trials of its Natural Hair Care products and Natural Skin Care Products or any of its other products; (v) Caleco will be able to obtain financing in order to meet the costs of the clinical studies of its "Liver Health" formulation, Natural Hair Care Products (LamiriShampoo, LamiriHair Conditioner, LamiriHair Tonic) and Natural Skin Care Products (LamiriGel and LamiriCreme); or (vi) Caleco will be able to control the costs of the clinical studies of its "Liver Health" formulation, Natural Hair Care Products (LamiriShampoo, LamiriHair Conditioner, LamiriHair Tonic) and Natural Skin Care Products (LamiriGel and LamiriCreme). Readers are cautioned not to place undue reliance on the forward-looking statements made in this press release.

Caleco Pharma Corp.

John Boschert, President

Contact Information